abstract |
The invention relates to medicine, in particular pharmacology, and concerns the use of a nasal composition containing the hexapeptide tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine or its pharmaceutically acceptable salt for the treatment of acute respiratory viral diseases (ARVI), in particular, caused by a virus flu. The claimed use of a nasal composition containing hexapeptide tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine or a pharmaceutically acceptable salt thereof for the treatment of acute respiratory viral diseases of ARVI. |